Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DRNA

Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis

Dicerna Pharmaceuticals logo

About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)

Advanced Chart

Key Stats

Today's Range
$38.22
$38.22
50-Day Range
$37.81
$38.25
52-Week Range
$19.06
$40.14
Volume
N/A
Average Volume
1.34 million shs
Market Capitalization
$2.99 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive DRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DRNA Stock News Headlines

Arrowhead Pharmaceuticals (NASDAQ: ARWR)
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
DRNA Jan 2022 22.500 call
DRNA Jul 2022 40.000 call(CONTR
See More Headlines

DRNA Stock Analysis - Frequently Asked Questions

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. The biopharmaceutical company earned $62.95 million during the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL).

Company Calendar

Last Earnings
11/09/2021
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRNA
CIK
1399529
Employees
302
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$112.75 million
Net Margins
-64.53%
Pretax Margin
-63.82%
Return on Equity
-103.08%
Return on Assets
-16.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.46
Quick Ratio
2.46

Sales & Book Value

Annual Sales
$164.31 million
Price / Sales
18.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.84 per share
Price / Book
20.77

Miscellaneous

Outstanding Shares
78,129,000
Free Float
70,160,000
Market Cap
$2.99 billion
Optionable
Optionable
Beta
0.80

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:DRNA) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners